PREP (Prolyl endopeptidase) primarily functions as a cytosolic serine protease that cleaves proline-containing peptides, regulating intracellular peptide turnover and modulating bioactive peptide signaling
[1]. Mechanistically, PREP interacts with pathways involved in neuropeptide maturation and degradation, impacting peptide-mediated neurotransmission and cellular signaling cascades
[2][3]. In disease models, PREP activity has been implicated in neurodegenerative disorders, including Alzheimer's disease, where abnormal peptide accumulation contributes to pathology
[4][5]. Compared with related isoforms such as DPP4 and FAP, PREP exhibits distinct substrate specificity for short proline-containing peptides, and its expression is predominantly cytosolic rather than membrane-bound
[1][6]. Pharmacological inhibition of PREP with small-molecule inhibitors has demonstrated modulation of peptide levels in both in vitro and in vivo models, supporting its role in cognitive and neurodegenerative research applications
[7][8]. These inhibitors selectively alter PREP activity without significantly affecting structurally similar serine proteases, allowing for isoform-specific experimental interventions
[6][7]. Therefore, PREP serves as a target for studying peptide-mediated signaling, neurodegeneration, and the functional consequences of peptide homeostasis in experimental neuroscience models
[3][4][8].